Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

German non-profit organization DEBRA Research GmbH, supporting those affected by epidermolysis bullosa (EB), and Denmark’s LEO Pharma announced a non-exclusive strategic partnership.

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

DEBRA Research and LEO Pharma enter strategic partnership to advance treatments for rare skin diseases: Munich, Germany Thursday, February 6, 2025, 10:00 Hrs [IST] DEBRA Research ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

The phase 3 DELTA TEEN trial evaluating Anzupgo 20 mg/g cream for the treatment of chronic hand eczema in adolescents has ...

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Under the agreement, LEO Pharma will be responsible for toripalimab’s distribution, promotion, sales, etc., in up to 32 countries, including all member states of the European Union (EU ...

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure the rights to promote and sell the PD-1 inhibitor in its home region.